By the time this study started, the therapeutic armamentarium for CD included conventional drugs such as salicylates (depending on guideline), antibiotics, immunomodulators, corticosteroids, tumor necrosis factor α antagonists (anti-TNF-α), e.g., infliximab, adalimumab, certolizumab pegol and infliximab biosimilar, and vedolizumab [6,7]. This evidence concerns the gene TNF and Cowden disease.